China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
82 hedge funds and large institutions have $1.38B invested in China Biologic Products Holdings, Inc. in 2018 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 31 reducing their positions, and 23 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
7% less capital invested
Capital invested by funds: $1.49B → $1.38B (-$103M)
10% less funds holding
Funds holding: 91 → 82 (-9)
26% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 31
39% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 23
45% less call options, than puts
Call options by funds: $10M | Put options by funds: $18.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$199M |
| 2 |
HSBC Holdings
London,
United Kingdom
|
+$72.7M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$62.8M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$32M |
| 5 |
YCMGA
York Capital Management Global Advisors
New York
|
+$31.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$57.8M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$43.3M |
| 3 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$25M |
| 4 |
BCIM
Black Creek Investment Management
Toronto,
Ontario, Canada
|
-$23.9M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$21.4M |
CBPO Hedge Fund Activity: Q3 2018 in Review
82 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q3 2018, worth a combined $1.38B — down 7% from $1.49B a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of CBPO and 14 opened new positions — a net loss of 9 holders — while 31 trimmed existing stakes and 23 added.
The largest buyer was Hillhouse Investment Management, adding an estimated $199M. The largest seller was Capital Research Global Investors, cutting an estimated $57.8M.
- 82 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q3 2018, down from 91 in Q2 2018.
- Funds reported $1.38B of China Biologic Products Holdings, Inc. stock for Q3 2018, down 7% quarter-over-quarter.
- 14 funds opened new China Biologic Products Holdings, Inc. positions in Q3 2018 and 23 closed out, a net change of -9 holders.
- The largest China Biologic Products Holdings, Inc. buyer in Q3 2018 was Hillhouse Investment Management, an estimated $199M added.
- The largest China Biologic Products Holdings, Inc. seller in Q3 2018 was Capital Research Global Investors, an estimated $57.8M sold.
Based on aggregated 13F filings for Q3 2018.